Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Nisoxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 10/20 | 1.00 |
| ▸ | SLC6A4 known ✓ | P31645 | 13/20 | 0.97 |
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.97 |
| ▸ | CHRM1 known ✓ | P11229 | 2/20 | 0.71 |
| ▸ | ADRA2B known ✓ | P18089 | 2/20 | 0.71 |
| ▸ | HTR2A known ✓ | P28223 | 2/20 | 0.71 |
| ▸ | HTR2C known ✓ | P28335 | 2/20 | 0.71 |
| ▸ | HRH1 known ✓ | P35367 | 2/20 | 0.71 |
| ▸ | OPRM1 known ✓ | P35372 | 2/20 | 0.71 |
| ▸ | DRD3 known ✓ | P35462 | 2/20 | 0.71 |
| ▸ | OPRK1 known ✓ | P41145 | 2/20 | 0.71 |
| ▸ | HTR2B known ✓ | P41595 | 2/20 | 0.71 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.71 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 2/20 | 0.71 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.97 |
| ▸ | TSHR | P16473 | 3/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nisoxetine SCHEMBL467262 | 1.00 | SLC6A2 (1.00) | SLC6A2PMP22SLC6A4CYP2D6CYP1A2 | |
| Nisoxetine SCHEMBL30026153 | 0.98 | SLC6A4 (1.00) | SLC6A2PMP22SLC6A4CYP2D6CYP1A2 | |
| Nisoxetine SCHEMBL124289 | 0.98 | SLC6A4 (1.00) | SLC6A2PMP22SLC6A4CYP2D6CYP1A2 | |
| Nisoxetine SCHEMBL29401038 | 0.98 | SLC6A4 (1.00) | SLC6A2PMP22SLC6A4CYP2D6CYP1A2 | |
| Nisoxetine SCHEMBL3897550 | 0.98 | SLC6A4 (1.00) | SLC6A2PMP22SLC6A4CYP2D6CYP1A2 | |
| Nisoxetine SCHEMBL3892886 | 0.98 | SLC6A4 (1.00) | SLC6A2PMP22SLC6A4CYP2D6CYP1A2 | |
| Nisoxetine SCHEMBL14973458 | 0.95 | SLC6A4 (0.94) | SLC6A2PMP22SLC6A4CYP2D6CYP1A2 | |
| Nisoxetine SCHEMBL4083146 | 0.92 | SLC6A4 (0.86) | SLC6A2PMP22SLC6A4CYP2D6CYP1A2 | |
| [3H]Nisoxetine SCHEMBL29463855 | 0.88 | SLC6A2 (1.00) | SLC6A2PMP22SLC6A4CYP2D6CYP1A2 | |
| Atomoxetine SCHEMBL1560986 | 0.85 | SLC6A2 (1.00) | SLC6A2PMP22SLC6A4CYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704826-A1 | COMPOSITIONS AND METHODS FOR TREATING POST-TRAUMATIC STRESS DISORDER | Yale University (US) | 2026-03-11 | — | — | EP | claimed |
| WO-2024226995-A1 | COMPOSITIONS AND METHODS FOR TREATING POST-TRAUMATIC STRESS DISORDER | YALE UNIVERSITY (US) | 2024-10-31 | — | — | WO | claimed |
| US-20230381168-A1 | ADJUNCTIVE THERAPY FOR DEPRESSION | ANEUROTECH BV (BE) | 2023-11-30 | — | — | US | claimed |
| US-20260098053-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | SAGE THERAPEUTICS INC (US) | 2026-04-09 | — | — | US | disclosed |
| US-20260083709-A1 | COMBINATION PHARMACOLOGICAL INTERVENTIONS FOR MULTIPLE MECHANISMS OF OBSTRUCTIVE SLEEP APNEA | APNIMED INC DELAWARE (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4704826-A1 | COMPOSITIONS AND METHODS FOR TREATING POST-TRAUMATIC STRESS DISORDER | Yale University (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-3976628-B1 | NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF | SAGE THERAPEUTICS LLC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-12558327-B2 | Methods and compositions for treating sleep apnea | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-12552829-B2 | Compositions and methods for treating CNS disorders | SAGE THERAPEUTICS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260027070-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | APNIMED INC DELAWARE (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260022091-A1 | POLYMORPHIC FORMS OF (R)-OXYBUTYNIN HYDROCHLORIDE | APNIMED INC DELAWARE (US) | 2026-01-22 | — | — | US | disclosed |
| CN-114729000-A | Compounds for the treatment of CNS disorders | 萨奇治疗股份有限公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2022115381-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS CROSS REFERENCE TO RELATED APPLICATION | SAGE THERAPEUTICS, ONC. (US) | 2022-06-02 | — | — | WO | disclosed |
| EP-3990469-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | Sage Therapeutics, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-3990468-A1 | COMPOUNDS FOR TREATING CNS DISORDERS | Sage Therapeutics, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-3990467-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | Sage Therapeutics, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| CN-114391019-A | Compositions and methods for treating CNS disorders | 萨奇治疗股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| EP-3976628-A1 | NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF | Sage Therapeutics, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| US-20220096401-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | NATIONAL INSTITUTES OF HEALTH | 2022-03-31 | — | — | US | disclosed |
| CN-114206900-A | Neuroactive steroids and compositions thereof | 萨奇治疗股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027070-A1 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | NTSR1, NTSR2, GPR39 | SLC6A2 6/4885SLC6A4 13/4885SLC6A3 96/4885 |
| US-12558327-B2 | Methods and compositions for treating sleep apnea | ADRA2A, HTR2A, ADRA2B | SLC6A2 4/4885SLC6A4 31/4885SLC6A3 62/4885 |
| US-20260083709-A1 | COMBINATION PHARMACOLOGICAL INTERVENTIONS FOR MULTIPLE MECHANISMS OF OBSTRUCTIVE SLEEP APNEA | CHRNA2, CHRNA3, ADRA2B | SLC6A2 4/4885SLC6A4 85/4885SLC6A3 69/4885 |
| US-20260022091-A1 | POLYMORPHIC FORMS OF (R)-OXYBUTYNIN HYDROCHLORIDE | CHRNB1, CHRM2, CHRND | SLC6A2 357/4885SLC6A4 1972/4885SLC6A3 1964/4885 |
| US-20260098053-A1 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS | GRIN2B, GRIN2C, GRIN2D | SLC6A2 30/4885SLC6A4 59/4885SLC6A3 24/4885 |
| US-12552829-B2 | Compositions and methods for treating CNS disorders | GRIN2C, GRIN2B, GRIN2A | SLC6A2 122/4885SLC6A4 561/4885SLC6A3 161/4885 |
| US-20230381168-A1 | ADJUNCTIVE THERAPY FOR DEPRESSION | HTR2A, HTR3B, HTR5A | SLC6A2 44/4885SLC6A4 25/4885SLC6A3 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.